Selected research
Industry Growth & Trends
Global Lung Cancer Diagnostic And Screening Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Lung Cancer Diagnostic And Screening market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Lung Cancer Diagnostic And Screening is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Lung Cancer Diagnostic And Screening is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Lung Cancer Diagnostic And Screening is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Lung Cancer Diagnostic And Screening market include Pfizer, F.Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Thermo Fisher Scientific, AstraZeneca Plc, Abbott Laboratories, Medtronic Plc, Danaher Corporation and Siemens Healthcare GmbH, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Lung Cancer Diagnostic And Screening market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Lung Cancer Diagnostic And Screening market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Lung Cancer Diagnostic And Screening market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Lung Cancer Diagnostic And Screening.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Lung Cancer Diagnostic And Screening market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Lung Cancer Diagnostic And Screening Market by Company
Pfizer
F.Hoffmann-La Roche AG
Bristol-Myers Squibb Company
Thermo Fisher Scientific
AstraZeneca Plc
Abbott Laboratories
Medtronic Plc
Danaher Corporation
Siemens Healthcare GmbH
FUJIFILM Corporation
KoninklijikePhilips N.V.
GE Healthcare Bio Sciences AB
Quest Diagnostics lIncorporated
Agilent Technologies lnc
Qiagen Inc.
Myriad Genetic Laboratories Inc.
NeoGenomics Laboratories Inc
Canon MedicalSystems Corporation
Eon Health Inc
Lung Cancer Diagnostic And Screening Segment by Type
Instrument
Consumables and Accessories
Lung Cancer Diagnostic And Screening Segment by Application
Hospital
Independent Diagnostic Laboratory
Lung Cancer Diagnostic And Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lung Cancer Diagnostic And Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lung Cancer Diagnostic And Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lung Cancer Diagnostic And Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Lung Cancer Diagnostic And Screening companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Instrument
- Consumables and Accessories
Applications
- Hospital
- Independent Diagnostic Laboratory
Companies covered
- Pfizer
- F.Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- Thermo Fisher Scientific
- AstraZeneca Plc
- Abbott Laboratories
- Medtronic Plc
- Danaher Corporation
- Siemens Healthcare GmbH
- FUJIFILM Corporation
- KoninklijikePhilips N.V.
- GE Healthcare Bio Sciences AB
- Quest Diagnostics lIncorporated
- Agilent Technologies lnc
- Qiagen Inc.
- Myriad Genetic Laboratories Inc.
- NeoGenomics Laboratories Inc
- Canon MedicalSystems Corporation
- Eon Health Inc
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Lung Cancer Diagnostic And Screening Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Lung Cancer Diagnostic And Screening Market Size by Region (2021-2032)
- 1.4.1 Global Lung Cancer Diagnostic And Screening Market Size by Region (2021-2026)
- 1.4.2 Global Lung Cancer Diagnostic And Screening Market Size by Region (2027-2032)
- 1.5 Key Regions Lung Cancer Diagnostic And Screening Market Size (2021-2032)
- 1.5.1 North America Lung Cancer Diagnostic And Screening Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Lung Cancer Diagnostic And Screening Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Lung Cancer Diagnostic And Screening Market Size Growth Rate (2021-2032)
- 1.5.4 South America Lung Cancer Diagnostic And Screening Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Lung Cancer Diagnostic And Screening Market Size Growth Rate (2021-2032)
2 Lung Cancer Diagnostic And Screening Market by Type
- 2.1 Type Introduction
- 2.1.1 Instrument
- 2.1.2 Consumables and Accessories
- 2.2 Global Lung Cancer Diagnostic And Screening Market Size by Type
- 2.2.1 Global Lung Cancer Diagnostic And Screening Market Size Overview by Type (2021-2032)
- 2.2.2 Global Lung Cancer Diagnostic And Screening Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Lung Cancer Diagnostic And Screening Market Size Forecasted by Type (2027-2032)
- 2.3 Global Lung Cancer Diagnostic And Screening Market Size by Regions
- 2.3.1 North America Lung Cancer Diagnostic And Screening Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Lung Cancer Diagnostic And Screening Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Lung Cancer Diagnostic And Screening Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Lung Cancer Diagnostic And Screening Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Lung Cancer Diagnostic And Screening Market Size Breakdown by Type (2021-2026)
3 Lung Cancer Diagnostic And Screening Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Independent Diagnostic Laboratory
- 3.2 Global Lung Cancer Diagnostic And Screening Market Size by Application
- 3.2.1 Global Lung Cancer Diagnostic And Screening Market Size Overview by Application (2021-2032)
- 3.2.2 Global Lung Cancer Diagnostic And Screening Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Lung Cancer Diagnostic And Screening Market Size Forecasted by Application (2027-2032)
- 3.3 Global Lung Cancer Diagnostic And Screening Market Size by Regions
- 3.3.1 North America Lung Cancer Diagnostic And Screening Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Lung Cancer Diagnostic And Screening Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Lung Cancer Diagnostic And Screening Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Lung Cancer Diagnostic And Screening Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Lung Cancer Diagnostic And Screening Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Lung Cancer Diagnostic And Screening Industry Trends
- 4.2 Lung Cancer Diagnostic And Screening Industry Drivers
- 4.3 Lung Cancer Diagnostic And Screening Industry Opportunities and Challenges
- 4.4 Lung Cancer Diagnostic And Screening Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Lung Cancer Diagnostic And Screening Revenue (2021-2026)
- 5.2 Global Lung Cancer Diagnostic And Screening Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Lung Cancer Diagnostic And Screening Key Company Headquarters & Area Served
- 5.4 Global Lung Cancer Diagnostic And Screening Company, Product Type & Application
- 5.5 Global Lung Cancer Diagnostic And Screening Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Lung Cancer Diagnostic And Screening Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Lung Cancer Diagnostic And Screening Players Market Share by Revenue in 2025
- 5.6.3 2025 Lung Cancer Diagnostic And Screening Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Pfizer
- 6.1.1 Pfizer Company Information
- 6.1.2 Pfizer Business Overview
- 6.1.3 Pfizer Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Pfizer Lung Cancer Diagnostic And Screening Product Portfolio
- 6.1.5 Pfizer Recent Developments
- 6.2 F.Hoffmann-La Roche AG
- 6.2.1 F.Hoffmann-La Roche AG Company Information
- 6.2.2 F.Hoffmann-La Roche AG Business Overview
- 6.2.3 F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 F.Hoffmann-La Roche AG Lung Cancer Diagnostic And Screening Product Portfolio
- 6.2.5 F.Hoffmann-La Roche AG Recent Developments
- 6.3 Bristol-Myers Squibb Company
- 6.3.1 Bristol-Myers Squibb Company Company Information
- 6.3.2 Bristol-Myers Squibb Company Business Overview
- 6.3.3 Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Bristol-Myers Squibb Company Lung Cancer Diagnostic And Screening Product Portfolio
- 6.3.5 Bristol-Myers Squibb Company Recent Developments
- 6.4 Thermo Fisher Scientific
- 6.4.1 Thermo Fisher Scientific Company Information
- 6.4.2 Thermo Fisher Scientific Business Overview
- 6.4.3 Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Thermo Fisher Scientific Lung Cancer Diagnostic And Screening Product Portfolio
- 6.4.5 Thermo Fisher Scientific Recent Developments
- 6.5 AstraZeneca Plc
- 6.5.1 AstraZeneca Plc Company Information
- 6.5.2 AstraZeneca Plc Business Overview
- 6.5.3 AstraZeneca Plc Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 AstraZeneca Plc Lung Cancer Diagnostic And Screening Product Portfolio
- 6.5.5 AstraZeneca Plc Recent Developments
- 6.6 Abbott Laboratories
- 6.6.1 Abbott Laboratories Company Information
- 6.6.2 Abbott Laboratories Business Overview
- 6.6.3 Abbott Laboratories Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Abbott Laboratories Lung Cancer Diagnostic And Screening Product Portfolio
- 6.6.5 Abbott Laboratories Recent Developments
- 6.7 Medtronic Plc
- 6.7.1 Medtronic Plc Company Information
- 6.7.2 Medtronic Plc Business Overview
- 6.7.3 Medtronic Plc Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Medtronic Plc Lung Cancer Diagnostic And Screening Product Portfolio
- 6.7.5 Medtronic Plc Recent Developments
- 6.8 Danaher Corporation
- 6.8.1 Danaher Corporation Company Information
- 6.8.2 Danaher Corporation Business Overview
- 6.8.3 Danaher Corporation Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Danaher Corporation Lung Cancer Diagnostic And Screening Product Portfolio
- 6.8.5 Danaher Corporation Recent Developments
- 6.9 Siemens Healthcare GmbH
- 6.9.1 Siemens Healthcare GmbH Company Information
- 6.9.2 Siemens Healthcare GmbH Business Overview
- 6.9.3 Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Siemens Healthcare GmbH Lung Cancer Diagnostic And Screening Product Portfolio
- 6.9.5 Siemens Healthcare GmbH Recent Developments
- 6.10 FUJIFILM Corporation
- 6.10.1 FUJIFILM Corporation Company Information
- 6.10.2 FUJIFILM Corporation Business Overview
- 6.10.3 FUJIFILM Corporation Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 FUJIFILM Corporation Lung Cancer Diagnostic And Screening Product Portfolio
- 6.10.5 FUJIFILM Corporation Recent Developments
- 6.11 KoninklijikePhilips N.V.
- 6.11.1 KoninklijikePhilips N.V. Company Information
- 6.11.2 KoninklijikePhilips N.V. Business Overview
- 6.11.3 KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 KoninklijikePhilips N.V. Lung Cancer Diagnostic And Screening Product Portfolio
- 6.11.5 KoninklijikePhilips N.V. Recent Developments
- 6.12 GE Healthcare Bio Sciences AB
- 6.12.1 GE Healthcare Bio Sciences AB Company Information
- 6.12.2 GE Healthcare Bio Sciences AB Business Overview
- 6.12.3 GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 GE Healthcare Bio Sciences AB Lung Cancer Diagnostic And Screening Product Portfolio
- 6.12.5 GE Healthcare Bio Sciences AB Recent Developments
- 6.13 Quest Diagnostics lIncorporated
- 6.13.1 Quest Diagnostics lIncorporated Company Information
- 6.13.2 Quest Diagnostics lIncorporated Business Overview
- 6.13.3 Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Quest Diagnostics lIncorporated Lung Cancer Diagnostic And Screening Product Portfolio
- 6.13.5 Quest Diagnostics lIncorporated Recent Developments
- 6.14 Agilent Technologies lnc
- 6.14.1 Agilent Technologies lnc Company Information
- 6.14.2 Agilent Technologies lnc Business Overview
- 6.14.3 Agilent Technologies lnc Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Agilent Technologies lnc Lung Cancer Diagnostic And Screening Product Portfolio
- 6.14.5 Agilent Technologies lnc Recent Developments
- 6.15 Qiagen Inc.
- 6.15.1 Qiagen Inc. Company Information
- 6.15.2 Qiagen Inc. Business Overview
- 6.15.3 Qiagen Inc. Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Qiagen Inc. Lung Cancer Diagnostic And Screening Product Portfolio
- 6.15.5 Qiagen Inc. Recent Developments
- 6.16 Myriad Genetic Laboratories Inc.
- 6.16.1 Myriad Genetic Laboratories Inc. Company Information
- 6.16.2 Myriad Genetic Laboratories Inc. Business Overview
- 6.16.3 Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Myriad Genetic Laboratories Inc. Lung Cancer Diagnostic And Screening Product Portfolio
- 6.16.5 Myriad Genetic Laboratories Inc. Recent Developments
- 6.17 NeoGenomics Laboratories Inc
- 6.17.1 NeoGenomics Laboratories Inc Company Information
- 6.17.2 NeoGenomics Laboratories Inc Business Overview
- 6.17.3 NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 NeoGenomics Laboratories Inc Lung Cancer Diagnostic And Screening Product Portfolio
- 6.17.5 NeoGenomics Laboratories Inc Recent Developments
- 6.18 Canon MedicalSystems Corporation
- 6.18.1 Canon MedicalSystems Corporation Company Information
- 6.18.2 Canon MedicalSystems Corporation Business Overview
- 6.18.3 Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.18.4 Canon MedicalSystems Corporation Lung Cancer Diagnostic And Screening Product Portfolio
- 6.18.5 Canon MedicalSystems Corporation Recent Developments
- 6.19 Eon Health Inc
- 6.19.1 Eon Health Inc Company Information
- 6.19.2 Eon Health Inc Business Overview
- 6.19.3 Eon Health Inc Lung Cancer Diagnostic And Screening Revenue, Global Share and Gross Margin (2021-2026)
- 6.19.4 Eon Health Inc Lung Cancer Diagnostic And Screening Product Portfolio
- 6.19.5 Eon Health Inc Recent Developments
7 North America
- 7.1 North America Lung Cancer Diagnostic And Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 7.3 North America Lung Cancer Diagnostic And Screening Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Lung Cancer Diagnostic And Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 8.3 Europe Lung Cancer Diagnostic And Screening Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Lung Cancer Diagnostic And Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Lung Cancer Diagnostic And Screening Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Lung Cancer Diagnostic And Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 10.3 South America Lung Cancer Diagnostic And Screening Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Lung Cancer Diagnostic And Screening Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Lung Cancer Diagnostic And Screening Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Lung Cancer Diagnostic And Screening Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst